Neorich Biopharma Tech Co Limited (NRBP) AI Stock Analysis

60 Followers

Neorich Biopharma Tech Co Limited

(Other OTC:NRBP)

Select Model

Rating:46Neutral

Price Target:$0.69▼(-22.05% Downside)

Action:reiterated

Date:10/30/26

The score is primarily weighed down by very weak financial performance (minimal revenue scale, heavy operating losses, negative equity, and ongoing negative operating/free cash flow). Technicals provide only partial support with price above short-term averages, but negative MACD limits confidence in momentum. Valuation is also a drag due to a negative P/E and no dividend yield.

Positive Factors

Reduced cash burnThe sharp reduction in operating cash outflow shows some progress in controlling cash consumption, even though operations remain cash negative. If maintained, this improvement could extend liquidity and give the company more time to stabilize its business model.

Negative Factors

Minimal scale and weak profitabilityExtremely low revenue and deeply negative operating results indicate that the core business has not yet demonstrated commercial scale or sustainable unit economics. The negative gross profit further weakens confidence that current operations can support durable earnings without major improvement.

Neorich Biopharma Tech Co Limited (NRBP) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $304.19K
Dividend Yield: ―
Average Volume (3M): 1,562
Price to Earnings (P/E): -0.2
Beta (1Y): 0.70
Revenue Growth: 167846.30%
EPS Growth: -295.83%
Country: US
Employees: 0
Sector: Healthcare
Sector Strength: 51
Industry: Specialty Business Services

Neorich Biopharma Tech Co Limited Business Overview & Revenue Model

Company Description

NeoRich BioPharma Tech Co., Ltd. is an international enterprise dedicated to biomedical R&D, precision medicine, cell & gene therapeutics, modernization of traditional Chinese medicine, anti-tumor formulations, and AI-driven drug development. The com...

Neorich Biopharma Tech Co Limited Financial Statement Overview

Summary

Financials indicate very high risk: revenue is extremely small, core profitability is deeply negative (EBIT/EBITDA far below revenue), and gross profit turned negative. The balance sheet is severely stressed with deeply negative equity and debt that is large relative to the tiny asset base. Cash flow remains negative (operating and free cash flow), with only partial improvement versus prior years, and reported net income is not supported by operating cash generation.

Income Statement

9Very Negative

Balance Sheet

6Very Negative

Cash Flow

12Very Negative

Neorich Biopharma Tech Co Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

NRBP against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ADXN	47Neutral	$3.33M	-0.46	-172.76%	―	-45.76%	-3.77%
NRBP	46Neutral	$304.19K	-0.20	21.06%	―	167846.30%	-295.83%
BJDX	44Neutral	$3.14M	-0.07	-125.01%	―	―	93.91%
MSPR	19Underperform	$1,425	0.00	80.67%	―	―	―

* Healthcare Sector Average

Performance Comparison

NRBP and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
NRBP	Neorich Biopharma Tech Co., Limited	0.88	-0.12	-12.00%
ADTX	Aditxt, Inc.	0.04	-1177.16	-100.00%
ADXN	Addex Therapeutics Ltd (ADR)	2.89	-5.71	-66.40%
MSPR	Msp Recovery, Inc.	0.01	-0.47	-97.92%
BJDX	Bluejay Diagnostics, Inc.	2.81	-21.99	-88.67%
AKAN	Akanda Corp	0.74	-28.29	-97.46%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 30, 2026

Neorich Biopharma Tech Co Limited AI Stock Analysis